ARMATA PHARMACEUTICALS, INC.
Ownership & governance
Executives 3Directors 7Avg age 62Avg tenure 3.9y
DB
Deborah Birx
Chief Executive Officer
Age 70Since 2023-07-10Profile →
+9
Executives3
DB
Deborah Birx→
Chief Executive Officer
Age 70Since 2023-07-10
DH
David House→
Director of Finance/CFO
Age 42Since 2024-08-15
PH
Peter Hubbard
Chief Operating Officer
——
Board of directors7
JP
Joseph Patti→
Director/Board Member
Age 62Since 2019-05-08
SS
Sarah Schlesinger→
Director/Board Member
Age 66Since 2020-02-11
OK
Odysseas Kostas→
Director/Board Member
Age 51Since 2020-02-11
RK
Robin Kramer→
Chairman
Age 60Since 2023-02-28
JH
Jules Haimovitz→
Chairman
Age 75Since 2021-05-31
DB
Deborah Birx→
Director/Board Member
Age 70Since 2023-07-10
DG
Daniel Gilmer→
Director/Board Member
—Since 2026-04-23
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| INNOVIVA, INC. | 68.31 % | 25,076,769 |
| Madison Asset Management LLC | 5.741 % | 2,107,675 |
| Vanguard Capital Management LLC | 0.9971 % | 366,028 |
| Millennium Management LLC | 0.7028 % | 257,992 |
| 683 Capital Management LLC | 0.3732 % | 137,000 |
Catalog · 2026-07-09
SEC officers13
| Name | Role | Since | Shares |
|---|---|---|---|
| David House | Chief Financial Officer | — | 25,000 |
| Jules Haimovitz | Chairman | — | - |
| Robin Kramer | Chairman | — | - |
| Daniel Gilmer | Director/Board Member | — | - |
| Deborah Birx | Director/Board Member | — | - |
| Deborah L. Birx | Director or executive officer | — | 362,458 |
| Joseph M. Patti, Ph.D | Director or executive officer | — | 243,024 |
| Joseph Patti | Director/Board Member | — | - |
SEC · as of 2026-07-17
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 17.5Range 15–20Analysts 2
15Mean 17.520
- Buy 2
Broker actions20
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Reiterated | Buy | 15 | 2026-09-23 |
| HC Wainwright & Co. | Maintained | Buy | 15 | 2026-02-23 |
| Jones Trading | Initiated | Buy | 15 | 2026-01-05 |
| HC Wainwright & Co. | Maintained | Buy | 9 | 2025-05-19 |
| HC Wainwright & Co. | Reiterated | Buy | 7 | 2024-12-19 |
| HC Wainwright & Co. | Reiterated | Buy | 7 | 2024-11-14 |
| HC Wainwright & Co. | Reiterated | Buy | 7 | 2024-11-12 |
| HC Wainwright & Co. | Reiterated | Buy | 7 | 2024-08-15 |
| HC Wainwright & Co. | Reiterated | Buy | 7 | 2024-07-11 |
| HC Wainwright & Co. | Reiterated | Buy | 7 | 2024-05-08 |
| HC Wainwright & Co. | Maintained | Buy | 7 | 2024-03-22 |
| HC Wainwright & Co. | Reiterated | Buy | 7 | 2023-08-14 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.